Subtopic Deep Dive
Intravenous Immunoglobulin Resistance in Kawasaki Disease
Research Guide
What is Intravenous Immunoglobulin Resistance in Kawasaki Disease?
Intravenous immunoglobulin resistance in Kawasaki disease refers to the failure of initial IVIG treatment to resolve fever and inflammation in 10-20% of patients, increasing risks of coronary artery aneurysms.
Approximately 10-20% of Kawasaki disease patients do not respond to a single dose of IVIG, requiring secondary therapies like corticosteroids (Newburger et al., 2004; 1922 citations). Cohort studies identify predictors such as elevated CRP, low albumin, and genetic factors. Management guidelines recommend adjunct treatments for refractory cases (Eleftheriou et al., 2013; 275 citations).
Why It Matters
IVIG resistance elevates coronary complication risks by 3-5 fold, necessitating predictors for early intervention (Newburger et al., 2004). Identifying resistance markers enables personalized protocols, reducing aneurysm rates from 25% to under 5% with adjunct steroids (Eleftheriou et al., 2013). Recent MIS-C overlaps highlight shared inflammatory pathways, informing biologics like infliximab (Henderson et al., 2020; 529 citations).
Key Research Challenges
Predicting IVIG Non-Responders
Biomarkers like CRP, albumin, and neutrophils predict resistance with 70-80% accuracy in cohorts (Newburger et al., 2004). Genetic variants in ITPKC and BLK genes link to susceptibility, but validation across populations is limited (Kuo et al., 2012). Developing reliable scores remains inconsistent across studies.
Optimal Secondary Therapies
Corticosteroids reduce fever duration by 2 days in resistant cases, but long-term coronary outcomes vary (Eleftheriou et al., 2013). Infliximab shows promise in small trials, yet randomized data is scarce. Balancing efficacy against infection risks challenges guidelines.
Distinguishing MIS-C Overlap
MIS-C mimics KD with IVIG resistance in 30-50% cases, complicating diagnosis (Pouletty et al., 2020; 539 citations). Shared vasculitis pathways require differential biomarkers (Sharma et al., 2021). Post-COVID cohorts demand updated protocols.
Essential Papers
Diagnosis, Treatment, and Long-Term Management of Kawasaki Disease
Jane W. Newburger, Masato Takahashi, Michael A. Gerber et al. · 2004 · Circulation · 1.9K citations
Background— Kawasaki disease is an acute self-limited vasculitis of childhood that is characterized by fever, bilateral nonexudative conjunctivitis, erythema of the lips and oral mucosa, changes in...
Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort
Marie Pouletty, Charlotte Borocco, Naïm Ouldali et al. · 2020 · Annals of the Rheumatic Diseases · 539 citations
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 1
Lauren A. Henderson, Scott Canna, Kevin G. Friedman et al. · 2020 · Arthritis & Rheumatology · 529 citations
Objective To provide guidance on the management of multisystem inflammatory syndrome in children (MIS‐C), a condition characterized by fever, inflammation, and multiorgan dysfunction that manifests...
Multi-System Inflammatory Syndrome in Children (MIS-C) Following SARS-CoV-2 Infection: Review of Clinical Presentation, Hypothetical Pathogenesis, and Proposed Management
Natasha Nakra, Dean A. Blumberg, Angel Herrera-Guerra et al. · 2020 · Children · 514 citations
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection may result in the multisystem inflammatory syndrome in children (MIS-C). The clinical presentation of MIS-C includes fever, se...
Multisystem inflammatory syndrome in children related to COVID-19: a systematic review
Levi Hoste, Ruben Van Paemel, Filomeen Haerynck · 2021 · European Journal of Pediatrics · 419 citations
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS–CoV‐2 and Hyperinflammation in Pediatric COVID‐19: Version 2
Lauren A. Henderson, Scott Canna, Kevin G. Friedman et al. · 2020 · Arthritis & Rheumatology · 409 citations
Objective To provide guidance on the management of Multisystem Inflammatory Syndrome in Children (MIS‐C), a condition characterized by fever, inflammation, and multiorgan dysfunction that manifests...
Kawasaki disease: pathophysiology and insights from mouse models
Magali Noval Rivas, Moshe Arditi · 2020 · Nature Reviews Rheumatology · 278 citations
Reading Guide
Foundational Papers
Start with Newburger et al. (2004; 1922 citations) for core guidelines on IVIG failure management, then Eleftheriou et al. (2013; 275 citations) for secondary therapy evidence.
Recent Advances
Study Pouletty et al. (2020; 539 citations) and Henderson et al. (2020; 529 citations) for MIS-C/KD resistance overlaps; Noval Rivas (2020; 278 citations) for pathophysiology.
Core Methods
Cohort scoring (Kobayashi); adjunct steroids; biologics (infliximab); mouse vasculitis models.
How PapersFlow Helps You Research Intravenous Immunoglobulin Resistance in Kawasaki Disease
Discover & Search
Research Agent uses searchPapers('IVIG resistance Kawasaki predictors') to retrieve 50+ papers including Newburger et al. (2004), then citationGraph reveals Eleftheriou et al. (2013) as a key node with 275 citations linking to steroid trials.
Analyze & Verify
Analysis Agent applies readPaperContent on Pouletty et al. (2020) to extract MIS-C resistance rates, verifies claims via verifyResponse (CoVe) against cohorts, and runPythonAnalysis on GRADE-scored evidence computes meta-analysis odds ratios for coronary risks.
Synthesize & Write
Synthesis Agent detects gaps in genetic predictors post-2012 via gap detection, then Writing Agent uses latexEditText and latexSyncCitations to draft protocols citing Kuo et al. (2012), with exportMermaid for treatment flowchart diagrams.
Use Cases
"Analyze IVIG resistance rates and predictors from cohort data in recent KD papers"
Research Agent → searchPapers → runPythonAnalysis (pandas meta-analysis on extracted rates from Newburger 2004 and Eleftheriou 2013) → statistical summary table with 95% CIs.
"Draft LaTeX review section on MIS-C vs KD IVIG resistance therapies"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Henderson 2020) → latexCompile → formatted PDF with cited guidelines.
"Find code for KD biomarker prediction models from papers"
Research Agent → paperExtractUrls (Kuo 2012) → paperFindGithubRepo → githubRepoInspect → runnable Python script for ITPKC variant scoring.
Automated Workflows
Deep Research workflow scans 50+ KD papers via searchPapers → citationGraph, generating structured reports on resistance predictors with GRADE grading. DeepScan applies 7-step CoVe chain to verify infliximab efficacy claims from Eleftheriou (2013). Theorizer synthesizes mouse model insights (Noval Rivas 2020) into IVIG resistance hypotheses.
Frequently Asked Questions
What defines IVIG resistance in Kawasaki disease?
Failure to defervesce within 36 hours after IVIG infusion, occurring in 10-20% of cases (Newburger et al., 2004).
What methods predict IVIG non-responders?
Kobayashi score uses CRP >10 mg/dL, albumin <3 g/dL, neutrophils >83%; genetic markers include ITPKC (Kuo et al., 2012).
What are key papers on IVIG resistance management?
Newburger et al. (2004; 1922 citations) outlines guidelines; Eleftheriou et al. (2013; 275 citations) details steroids for refractory KD.
What open problems exist in IVIG resistance research?
Lack of large RCTs for biologics like infliximab; distinguishing MIS-C overlaps (Pouletty et al., 2020); population-specific genetic predictors.
Research Kawasaki Disease and Coronary Complications with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Intravenous Immunoglobulin Resistance in Kawasaki Disease with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers